Prostate cancer screening remains to be demonstrated

The recent release of two large randomized studies indicates that, if it is the power of detection, it is the best, small, says a new report in CA: A Cancer Journal for Clinicians. , The Otis W. Brawley, MD, American Cancer Society and Donna Ankerst, Ph.D., and Ian M. Thompson, MD from the University of Texas Health Science Center at San Antonio, the audit said, because prostate cancer among men almost everywhere, because age, it is clear that the purpose of seeking more cancer "is not acceptable. Instead, public health principles, require that the screening must be the risk of death from prostate cancer, suffering from prostate cancer, or reducing health care costs compared with no screening scenario . The authors speculate, prostate cancer screening has not yet reached any of these standards are in compliance.

No larger medical group, including the American Cancer Society, which is currently recommended for routine prostate cancer screening for men of average risk. In the United States, prostate cancer is a man to six men in his lifetime. Since the mid-1980s, with screening for prostate specific antigen (PSA) of blood has more than doubled the risk of prostate cancer diagnosis. The review indicates a decline in mortality from prostate cancer has been observed since that time, but the relative contribution of the PSA test, unlike other factors, such as improved treatment, was uncertain .

The report indicates a modeling study with the National Cancer Institute's Surveillance, Epidemiology, and End Results (SEER) Registries estimates that more than a quarter of white cancers (29%) and almost half of black cancers (44%) have been overdiagnosed cancer. A similar model with data from Europe believes that 50% overdiagnosis sentence. The authors say that patients diagnosed with clinically insignificant tumors were unnecessary diagnostic tests and unnecessary treatments, and suffer psychosocial damage. They are also marked "a cancer patient," the negative economic consequences. Similarly, say the authors, overdiagnosis serious 5 year survival statistics, as well as lack of progress in cancer control.

The report said that the future of the prostate is improved testing, better evaluation methods, a man, the risk of prostate cancer, and prevention strategies, including the use of finasteride , a drug for the treatment of urinary symptoms related to the prostate. In another, but with Editorial, Peter Boyle, Ph.D., D.Sc., the International Council for Prevention Research Institute, Lyon, France and report co-author Dr. Brawley said, "the real impact and tragedy of prostate cancer screening is to double the lifetime risk of diagnosis of prostate cancer with little or no limit the risk of dying from this disease. "They say, in 1985, before PSA screening for, a man was American by 8.7 percent risk of life, the diagnosis of prostate cancer with 2.5% and lifetime risk of dying from disease.

Twenty years later, in 2005, an American, a man of 17 per cent risk of living with the diagnosis of prostate cancer and 3% risk of dying from the disease. They add that even in the best case the application of the results of a European study found that PSA has led to a 20 percent risk of death, man chooses to reduce the risk screening prostate cancer death of a lifetime risk of 3% over a lifetime risk of 2.4%. In return, he doubled the chances of prostate cancer in a patient, the risk for diagnosis has increased by about nine per cent in less than 17%.

They come to the conclusion that "men should now quantifiable risks and benefits with a PSA test with their doctor and go into the decision," and that "the weight of the decision should not patients with knee .